Have a feature idea you'd love to see implemented?
Let us know!
HOLX Hologic Inc
Price (delayed)
$78.72
Market cap
$18.28B
P/E Ratio
26.68
Dividend/share
N/A
EPS
$2.95
Enterprise value
$18.4B
Hologic, Inc. is a medical technology company primarily focused on women’s health; it sells medical devices for diagnostics, surgery, and medical imaging. In late November 2013, activist investor Carl Icahn
Highlights
The EPS has surged by 51% since the previous quarter and by 51% year-on-year
Hologic's net income has surged by 50% QoQ and by 45% YoY
Hologic's quick ratio has decreased by 13% YoY but it has increased by 3.4% QoQ
HOLX's equity is down by 4.5% year-on-year but it is up by 2.2% since the previous quarter
Key stats
What are the main financial stats of HOLX
Market
Valuations
Earnings
Shares outstanding
232.27M
Market cap
$18.28B
Enterprise value
$18.4B
Price to earnings (P/E)
26.68
Price to book (P/B)
3.71
Price to sales (P/S)
4.63
EV/EBIT
20.28
EV/EBITDA
15.12
EV/Sales
4.62
Revenue
$3.99B
EBIT
$907.4M
EBITDA
$1.22B
Free cash flow
$1.01B
Per share
Balance sheet
Liquidity
EPS
$2.95
Free cash flow per share
$4.32
Book value per share
$21.21
Revenue per share
$17
TBVPS
$20.93
Total assets
$8.89B
Total liabilities
$3.94B
Debt
$2.56B
Equity
$4.95B
Working capital
$2.99B
Debt to equity
0.52
Current ratio
3.99
Quick ratio
3.06
Net debt/EBITDA
0.1
Margins
Efficiency
Dividend
EBITDA margin
30.5%
Gross margin
54.4%
Net margin
17.6%
Operating margin
19.7%
Return on assets
8%
Return on equity
14.4%
Return on invested capital
22.6%
Return on capital employed
11.5%
Return on sales
22.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HOLX stock price
How has the Hologic stock price performed over time
Intraday
0.87%
1 week
1.52%
1 month
-2.99%
1 year
9.47%
YTD
10.17%
QTD
-3.36%
Financial performance
How have Hologic's revenue and profit performed over time
Revenue
$3.99B
Gross profit
$2.17B
Operating income
$784.3M
Net income
$701.5M
Gross margin
54.4%
Net margin
17.6%
Hologic's net income has surged by 50% QoQ and by 45% YoY
The company's net margin rose by 49% QoQ and by 47% YoY
Hologic's operating income has increased by 45% QoQ and by 18% YoY
The operating margin has grown by 44% from the previous quarter and by 19% YoY
Growth
What is Hologic's growth rate over time
Valuation
What is Hologic stock price valuation
P/E
26.68
P/B
3.71
P/S
4.63
EV/EBIT
20.28
EV/EBITDA
15.12
EV/Sales
4.62
The EPS has surged by 51% since the previous quarter and by 51% year-on-year
The stock's price to earnings (P/E) is 22% less than its last 4 quarters average of 34.0 and 6% less than its 5-year quarterly average of 28.4
HOLX's price to book (P/B) is 16% lower than its 5-year quarterly average of 4.4 but 3.1% higher than its last 4 quarters average of 3.6
HOLX's equity is down by 4.5% year-on-year but it is up by 2.2% since the previous quarter
HOLX's price to sales (P/S) is 16% higher than its 5-year quarterly average of 4.0 and 5% higher than its last 4 quarters average of 4.4
Efficiency
How efficient is Hologic business performance
Hologic's return on assets has surged by 54% QoQ and by 54% YoY
The ROE has soared by 52% from the previous quarter and by 52% YoY
HOLX's return on invested capital is up by 36% since the previous quarter and by 22% year-on-year
The return on sales is up by 34% since the previous quarter and by 18% year-on-year
Dividends
What is HOLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HOLX.
Financial health
How did Hologic financials performed over time
The total assets is 126% higher than the total liabilities
Hologic's quick ratio has decreased by 13% YoY but it has increased by 3.4% QoQ
Hologic's current ratio has decreased by 10% YoY
The company's debt is 48% lower than its equity
The company's debt fell by 10% YoY
Hologic's debt to equity has decreased by 5% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.